Novartis to report cancer drug data at SABCS and ASH 2011 Zenopa SABCS highlights will include phase III data on everolimus for advanced breast cancer, as well as further findings on Zometa and BKM120. Meanwhile, the ASH presentations will focus on approved and developmental therapies including Trajenta, Exjade, ... Novartis to showcase 160 presentations on breast cancer, hematological disease ... |
